Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Company Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Key Stats

• Today's Range: $5.35 to $5.62
• 50-Day Range: $4.91 to $6.97
• 52-Week Range: $4.69 to $11.90
• Volume: 45,414 shs
• Average Volume: 249,419 shs
• Market Capitalization: $167.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.67
• Consensus Rating: Buy

Acrivon Therapeutics Stock Analysis - MarketRank™

Acrivon Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 660th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Acrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Acrivon Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acrivon Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acrivon Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acrivon Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.47% of the float of Acrivon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Acrivon Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Acrivon Therapeutics has recently decreased by 33.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acrivon Therapeutics does not currently pay a dividend.

Dividend Growth

Acrivon Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.47% of the float of Acrivon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Acrivon Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Acrivon Therapeutics has recently decreased by 33.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.22

News Sentiment

Acrivon Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Acrivon Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Acrivon Therapeutics is held by insiders.

Percentage Held by Institutions

71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACRV Stock Analysis - Frequently Asked Questions

How have ACRV shares performed this year?

Acrivon Therapeutics' stock was trading at $6.02 at the beginning of 2025. Since then, ACRV shares have decreased by 10.5% and is now trading at $5.39.
View the best growth stocks for 2025 here.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.08.

When did Acrivon Therapeutics IPO?

Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

Who are Acrivon Therapeutics' major shareholders?

Top institutional investors of Acrivon Therapeutics include Citadel Advisors LLC (6.81%), Marshall Wace LLP (1.92%), Acorn Capital Advisors LLC (1.30%) and Northern Trust Corp (0.38%). Insiders that own company stock include Perceptive Advisors Llc, Ra Capital Management, LP and Ltd Chione.
View institutional ownership trends.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acrivon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 3/26/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACRV
• CIK: 1781174
• Web: www.acrivon.com
• Phone: 617-207-8979
• Fax: N/A
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.67
• High Stock Price Target: $30.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +339.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-60,390,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.95%
• Return on Assets: -43.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.75
• Quick Ratio: 12.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.38 per share
• Price / Book: 1.00

Miscellaneous

• Outstanding Shares: 31,136,000
• Free Float: 28,489,000
• Market Cap: $167.82 million
• Optionable: Not Optionable
• Beta: 0.85